312 results about "Tuberculoma" patented technology

The invention discloses a pulmonary tuberculosis image classification and recognition system based on feature aggregation and focus area perception, and the system comprises the steps: carrying out the local and global feature extraction and fusion of a pulmonary tuberculosis image through a feature extraction subsystem; the method comprises the following steps: constructing a graph structure of fusion features through a pulmonary tuberculosis classification subsystem based on focus area perception, dynamically aggregating node information, realizing three classifications of health, tuberculosis and disease but non-tuberculosis in a first stage, and carrying out active tuberculosis and old tuberculosis subdivision in a second stage on a pulmonary tuberculosis image in combination with focus structure features; through an unbalanced data set processing subsystem based on characteristic aggregation and dynamic data amplification, under-sampling is carried out on the characteristic that active tuberculosis data samples are large by adopting a characteristic aggregation technology, and resampling is carried out on old tuberculosis with few data samples by implementing a dynamic data amplification strategy; and key information learned from active tuberculosis categories is reserved through a knowledge distillation mechanism, so that more accurate focus recognition and classification are realized.

The invention discloses a tuberculosis onset risk assessment method and model, and relates to the technical field of medicines.The tuberculosis onset risk assessment method comprises the steps that tuberculosis epidemiological investigation is conducted, and the tuberculosis epidemiological investigation comprises collecting questionnaire data through screening infection detection, chest digital X-ray imaging and laboratory examination; based on the collected questionnaire data, in combination with the basic information, contact history, symptom expression and infection detection result of the investigated person, a primary database of tuberculosis risk assessment is constructed for the latent tuberculosis infected person. According to the tuberculosis onset risk assessment method and model provided by the invention, various epidemiological survey data, individual basic information, contact history, symptom expression and laboratory detection results are integrated, so that the tuberculosis onset risk of a latent infected person can be assessed more comprehensively and accurately, and misdiagnosis and missed diagnosis conditions are reduced; based on an accurate risk assessment result, high-risk crowds are identified more effectively, and corresponding prevention and control measures are taken.

The invention discloses an ore collection device multi-parameter optimization design method based on deep sea tuberculosis grading, and the method employs a discrete genetic algorithm to carry out the overall optimization of a plurality of design parameters of an ore collection device, and improves the collection efficiency. An elite retention strategy and a uniform two-point crossover method are introduced, several individuals with the highest fitness are selected as elite individuals, two points are randomly selected from gene strings of two parent individuals according to the uniform two-point crossover method, and then gene segments between the two points are exchanged to generate new individuals, so that exploration of new parameter combinations is facilitated, population diversity is increased, and the method is suitable for large-scale popularization and application. Therefore, a better design solution can be found; according to the method, a maximum likelihood method is adopted to estimate parameters of marginal probability density functions of the size and mass of the nodule, and a size-mass joint probability distribution function of nodule particles is constructed, so that the size and mass distribution of the nodule can be more accurately fitted, and a more real seabed environment model is created for the subsequent design of a mineral collection device; and relatively real seabed tuberculosis particle distribution is provided.

The invention belongs to the field of biological medicine, and relates to a tuberculosis molecular marker combination and application thereof. Specifically, the invention relates to a molecular marker combination, which comprises (A) nucleic acid for coding GLRX protein, and one or more of nucleic acid for coding FCGR1A protein, nucleic acid for coding IFITM1 protein and nucleic acid for coding UBE2L6 protein; or (B) a GLRX protein, and one or more selected from the group consisting of an FCGR1A protein, an IFITM1 protein, and a UBE2L6 protein. The molecular marker combination can effectively diagnose the active tuberculosis or effectively distinguish the active tuberculosis from latent tuberculosis infection and normal control, and has high sensitivity and specificity.

The invention discloses a primer composition and application thereof. According to the invention, a group of primer compositions is obtained aiming at mycobacterium tuberculosis complex group identification and drug resistance related genes thereof. The primer composition can be combined with nucleic acid matrix-assisted laser desorption ionization time-of-flight mass spectrometry to detect a mycobacterium tuberculosis complex group, and can also detect the mutation conditions of 18 drug-resistant genes and 92 gene mutations related to drug resistance of 21 common first-line and second-line antituberculous drugs / types in the mycobacterium tuberculosis complex group. The medication is guided. Based on a MassARRAY technical platform, the primer composition has the advantages of good accuracy, high sensitivity, short required time and high efficiency when being used for detecting the mycobacterium tuberculosis complex group and the drug resistance thereof, is suitable for various sample types, can meet clinical detection requirements, is beneficial to clinical diagnosis and medication guidance of mycobacterium tuberculosis, and realizes precise treatment of pulmonary tuberculosis.

Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a Mycobacterium tuberculosis (Mtb) RelA-SpoT homolog (RSH) protein, RelMtb, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3α) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of Mtb infections are also provided.

The invention belongs to the field of tuberculosis diagnosis, and particularly relates to an application of a KNCN recombinant protein in tuberculosis diagnosis. The KNCN recombinant protein can specifically and efficiently capture various tuberculosis antigens, the KNCN protein can capture several tuberculosis antigens in a tuberculosis patient specimen at the same time, and by expressing and purifying the recombinant KNCN protein, the captured binding antigen is detected.

The invention discloses a detection kit and method for Mycobacterium tuberculosis complex and rifampicin drug-resistant mutation, and belongs to the technical field of biologication.A Taqman probe and a molecular beacon are combined, a fluorescent signal is generated based on a Taq enzyme hydrolysis fluorescent probe, the fluorescent signal is accumulated, and the molecular beacon is used for detecting the drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation. According to two technical principles that a molecular beacon and a fluorescent product are hybridized to generate a fluorescent signal, fluorescent PCR amplification is adopted for detection of one target spot in a monochromatic fluorescent channel, and a melting curve mode of a probe and a target gene is adopted for detection of the other target spot. Therefore, two target spots can be detected and analyzed in a monochromatic fluorescence channel at the same time. Single-tube multiple detection is achieved, and mycobacterium tuberculosis complex group detection and mycobacterium tuberculosis rifampicin drug-resistant mutation site detection can be achieved at the same time.

The invention provides a compound as shown in a formula (I), a stereoisomer thereof, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a crystal form thereof, an isotope derivative thereof, a prodrug thereof and a metabolite thereof. The solvate or hydrate of the compound can be used for preparing a pharmaceutical composition for treating and / or preventing diseases related to mycobacterium tuberculosis and / or nontuberculous mycobacterium. The compound provided by the invention has an excellent bactericidal effect and strong specificity, has no cross resistance with the existing antituberculosis drugs, and provides a breakthrough direction for treatment of drug-resistant tuberculosis.

The invention discloses a cytokine combination for distinguishing active tuberculosis from latent tuberculosis infection. The invention also provides an application of the cell factor combination in establishing a machine learning model for distinguishing active tuberculosis and latent tuberculosis infection, and provides a machine learning model for distinguishing active tuberculosis and latent tuberculosis infection based on the application. And inputting the expression level of each cytokine in the cytokine combination of a sample to be detected into the machine learning model as an input variable, and judging whether the sample is an active tuberculosis sample or a tuberculosis latent infection sample based on an output result of the machine learning model. The cell factor combination is combined with the machine learning model to distinguish the active tuberculosis and the latent tuberculosis infection, the specificity reaches 66.67%-83.33%, the sensitivity reaches 92.86%-100%, the accuracy reaches 90%, and the method can be used for accurately distinguishing the active tuberculosis and the latent tuberculosis infection.

The invention discloses an electrochemical biosensor for detecting mycobacterium tuberculosis. The sensor takes a porous membrane as a base material, the inner wall of a pore channel of the porous membrane is co-modified with a polydopamine (PDA) and conductive carbon material composite layer, and an amino-modified specific capture probe based on a mycobacterium tuberculosis ESAT-6 gene is fixed on a modification layer through covalent binding. When a target gene is captured by a probe, the volume effect of the target gene causes blockage of a porous channel of the porous membrane, so that electrochemical signals (such as current) of the sensor are changed, and high-sensitivity and specific detection of mycobacterium tuberculosis is realized. According to the invention, a porous structure, biological probe specific fixation and an electrochemical signal conversion technology are combined, and a novel efficient tool is provided for rapid diagnosis of tuberculosis.

The invention discloses a method for establishing indirect ELISA (enzyme-linked immunosorbent assay) for detecting mycobacterium bovis Lprl, which comprises the following steps: preparing mycobacterium bovis Lprl protein, taking the purified protein as an antigen, and determining conditions such as optimal antigen coating concentration, serum dilution, serum incubation time, secondary antibody dilution concentration, incubation time and the like. The established indirect ELISA detection method does not have cross reaction with other bovine pathogens, the specificity is good, the detection accuracy is high, and the total coincidence rate of test results of intradermal allergy with bovine tubercle bacillus is 95.8%; the intra-batch variation coefficient of the detected samples is 2.43%-3.61%, the inter-batch variation coefficient is 2.83%-3.96%, and the intra-batch variation coefficient and the inter-batch variation coefficient are both smaller than 10%. A new diagnosis target is developed, the established indirect ELISA method has the characteristics of high sensitivity, strong specificity, good repeatability and the like, the operation is easy, and a new method is provided for the detection work of the mycobacterium bovis.

A multi-modal AI model for assisting knee joint tuberculosis diagnosis belongs to the field of assisting knee joint tuberculosis diagnosis and comprises a 3D image modal input module, a text modal input module, a test result modal input module, a multi-modal feature fusion module and a large language module. Aiming at the problems that the early diagnosis time of knee joint tuberculosis is too long and subjective interpretation is different, the diagnosis accuracy can be improved while the diagnosis time is shortened; according to the invention, an M3D model framework is optimized, CT / MRI images, laboratory indexes and text data are fused, and a multi-modal feature interaction auxiliary diagnosis system is constructed; according to the invention, accurate identification of early lesions of knee joint tuberculosis is realized, the misdiagnosis rate is reduced, and efficient and objective quantitative decision support is provided for clinic; according to the invention, the problems of high misdiagnosis rate and long flow caused by insufficient specificity in early diagnosis and examination of knee joint tuberculosis are solved through technical innovation.

The present invention provides an electrochemical aptamer sensor for detecting Mycobacterium tuberculosis ESAT‑6 antigen. The sandwich electrochemical biosensor uses a new type of MXene@Hemin‑AuNPs nanozyme as a signal amplifier and N‑CNTs‑AuNPs as a sensing interface to detect the Mycobacterium tuberculosis-specific antigen ESAT‑6 in the serum of tuberculosis patients, providing a new method for the diagnosis of tuberculosis.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

The present invention discloses a kit for diagnosing active tuberculosis. The kit includes a substance for detecting IFIT3 protein. Compared with healthy people and latent tuberculosis infected people, the expression of IFIT3 gene in PBMCs of active tuberculosis patients is significantly increased; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from latent tuberculosis infected people; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from healthy people. Therefore, IFIT3 protein and / or IFIT3 gene can be used as a marker to diagnose active tuberculosis. The present invention has great application value.

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

Provided is a method for rapidly detecting Mycobacterium tuberculosis. The method comprises using a primer pair for detecting Mycobacterium tuberculosis, which primer pair comprising an upstream primer and a downstream primer; wherein the upstream primer comprises a nucleotide sequence as shown in SEQ ID NO: 1 or 2, and the downstream primer comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 3-6. The method can rapidly and accurately detect the RNA of MTB viable bacteria in a biological sample with high sensitivity, reduces the detection limit by up to 1000 times compared with existing NASBA kits, reduces the requirements for templates, and provides a better option for the real-time detection of MTB.

The application belongs to the technical field of biological medicine, and particularly relates to a blood Mycobacterium tuberculosis complex free nucleic acid detection kit and a detection method. The application first proposes a kit, wherein a PCR detection reagent group and a CRISPR / Cas12a detection reagent group are arranged in the kit; the PCR detection reagent group comprises a forward primer and a reverse primer which target a complex target; the sequence of the forward primer is overlapped with or complementary to the recognition region of the crRNA sequence, or the sequence of the reverse primer is overlapped with or complementary to the recognition region of the crRNA sequence.

The invention discloses a detection system and method for identifying mycobacteria and drug resistance genes of the mycobacteria based on nanopore sequencing, and relates to the field of biological medicine, the detection system comprises a specific targeted enrichment module, a nanopore sequencing module and a biological information analysis module; the specific targeted enrichment module comprises a probe combination, and the probe combination covers a mycobacterium tuberculosis complex conservative identification gene, species-specific genes of common nontuberculous mycobacteria and mycobacterium leprosy, and full-length or partial sequences of drug resistance related genes in a targeted manner; by utilizing the characteristics of nanopore length reading length and real-time sequencing and a tuberculosis specific targeted enrichment strategy, accurate identification of a mycobacterium tuberculosis complex group, synchronous typing of 42 mycobacteria, analysis of 24 drug-resistant genes, and efficient detection of structural variation and low-abundance heterogeneity drug-resistant mutation are realized, the detection period is shortened, the detection cost is reduced, and the detection efficiency is improved. And a comprehensive and reliable technical basis is provided for accurate diagnosis and treatment of mycobacterium infection.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The present invention provides a CRISPR system and a kit for detecting drug-resistant tuberculosis, which belong to the technical field of drug-resistant tuberculosis detection. The CRISPR system includes AaCas12b and sgRNA; the sgRNA includes a first sgRNA targeting the tuberculosis-specific sequence IS6110; and also includes a second and a third sgRNA targeting the drug-resistant tuberculosis rpoBS531L and / or katGS315T mutation sites. The present invention is based on the Crispr-AaCas12b system, targeting the tuberculosis-specific sequence IS6110 and the most common mutation sites of drug-resistant tuberculosis. By selecting PAM and adjusting the length of the sgRNA spacer binding region and artificially introducing base mismatches, Crispr-AaCas12b can specifically recognize drug-resistant mutation sites and does not recognize wild-type sequences; drug-resistant tuberculosis is quickly and accurately detected by fluorescence signal monitoring.

The invention relates to a method for detecting activation of specific T cells after tuberculosis infection and application of the method. Specifically, the invention provides a reagent combination for detection, and the reagent combination comprises an anti-CD4 antibody (CD4 antibody), an anti-CD154 antibody (CD154 antibody), an IFN-gamma detection antibody and a tuberculosis specific antigen. According to the method, through peripheral whole blood collection, PBMC cell separation, T cell activation (activation), activation termination (blocking), antibody labeling, membrane rupture, fixation, intracellular cytokine dyeing, flow cytometry detection and result analysis and judgment, the ratio of the expression IFN-gamma cells in the CD4 + CD154 + cells can be rapidly and accurately determined, and by combining an ROC curve and a constructed judgment standard, the content of the IFN-gamma cells in the CD4 + CD154 + cells can be determined, and the content of the IFN-gamma cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells can be determined. And the sample to be detected is judged to be in a positive / negative / gray region, so that whether a patient is infected by the mycobacterium tuberculosis or not can be more accurately diagnosed, especially aiming at a whole blood sample from a special crowd.

The invention relates to a mycobacterium tuberculosis EspB polyclonal antibody as well as a preparation method and application thereof. The purified EspB antibody has good detection specificity, only reacts with mycobacteria, and does not react with other common pneumonia pathogenic bacteria. The EspB polyclonal antibody specifically recognizes mycobacteria EspB, comprises mycobacterium tuberculosis and nontuberculous mycobacteria (NTM) EspB which grows slowly and rapidly, and can be used for detecting tuberculosis and NTM diseases.

The invention discloses a gene marker for diagnosing latent tuberculosis infection and application of the gene marker, and belongs to the technical field of biological medicine. According to the present invention, the latent tuberculosis infection early diagnosis marker is screened based on the peripheral blood whole genome DNA methylation map, the new target is provided for the diagnosis of latent tuberculosis infection, the diagnosis efficiency of the marker is evaluated through pyrosequencing, the corresponding detection kit and the use method are developed, and the rapid and accurate diagnosis of latent tuberculosis infection is achieved.

To provide monoclonal antibodies specific to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.SOLUTION: The present invention provides a monoclonal anti-PIM6 / LAM antibody, or an antigen-binding portion thereof, that specifically binds to an epitope present in LAM and PIM6, the epitope including at least one polymannose structure. The anti-PIM6 / LAM antibody includes CDR1 light chain variable region, CDR2 light chain variable region, CDR3 light chain variable region, CDR1 heavy chain variable region, CDR2 heavy chain variable region, and CDR3 heavy chain variable region, each including a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention relates to a spinal infection and tuberculosis intelligent diagnosis method based on an image large model, the core idea of the method is pre-training of a base and hierarchical fine tuning, that is, firstly, a general spinal image visual large model is trained based on a DINOv2 algorithm by using mass unmarked spinal MRI data, so that the spinal image visual large model masters the anatomical structure and basic pathological characteristics of the spinal column; and then a two-stage cascaded diagnosis network is designed on the base, so that the problems of whether infection exists or not and the infection type are solved respectively. The problems that in spinal infection differential diagnosis, labeling data is deficient and the feature extraction capacity is insufficient are solved, a DINOv2 self-supervised pre-training technology is utilized to construct a visual feature base model, automatic screening of spinal infectious diseases and accurate differential diagnosis of infection subtypes are achieved through a hierarchical two-stage reasoning architecture, and the accuracy of the spinal infection differential diagnosis is improved. Dependence on annotation data is greatly reduced, and identification accuracy of difficult cases is remarkably improved.

The invention discloses a nanometer antibody of mycobacterium tuberculosis early secretory protein ESAT-6 and application thereof, relates to the technical field of antibody recombination and genetic engineering antibodies, and is characterized by providing two nanometer antibodies AEN1 and AEN5 which are derived from a total synthesis alpaca nanometer antibody yeast display library and are combined with ESAT-6 in high affinity, DNA sequences for coding the AEN1 and the AEN5, a carrier containing the DNA, a carrier containing the carrier containing the DNA, and a carrier containing the carrier containing the carrier containing the DNA. The invention relates to a vector, a host cell containing the vector, and a method for preparing AEN1 and AEN5 by utilizing genetic engineering. And the method for quantitatively detecting the ESAT-6 by using the double-antibody sandwich ELISA is established. Detection on clinical specimens of tuberculosis shows that the sensitivity of the diagnosis method is 94.9%, and the specificity is 100%. The antibody is used for preparing gold-labeled rapid test paper, and the ESAT-6 can be rapidly detected from serum of a mycobacterium tuberculosis infected patient.